In Q1 FY2026, Geron reported revenue of $51.8 million, up 30.9% year-over-year, driven by product sales. The company achieved operating income of $0.2 million, a significant improvement from a loss of $16.7 million a year ago. Net loss narrowed to $3.6 million from $19.7 million, reflecting improved cost management. Cash and equivalents stood at $68.9 million, with long-term debt of $119.8 million.
•Revenue grew 30.9% YoY to $51.8 million.
•Operating income turned positive at $0.2 million.
•Net loss improved 81.6% to $3.6 million.
•Cash position of $68.9 million with $119.8 million in long-term debt.
Informational summary based on SEC XBRL figures · generated by deepseek-v4-flash. Not investment advice.
Geron Corporation, a commercial-stage biopharmaceutical company develops therapeutics products for oncology. The company's product pipeline includes RYTELO, a telomerase inhibitor for the treatment of adult patients with low- to intermediate-1 risk myelodysplastic syndromes with transfusion-dependent anemia.
Its portfolio also includes IMerge which is in Phase 3 clinical trial for the treatment of lower-risk myelodysplastic syndromes, IMpactMF that is in Phase 3 for the treatment of relapsed/refractory myelofibrosis, Impress which is in Phase 2 clinical trial to treat higher risk myelodysplastic syndromes and acute myeloid leukemia (AML), IMproveMF which is in Phase 1 clinical trial for the treatment of frontline myelofibrosis, and IMAGINE which is in phase 1/2 clinical trial for the treatment of relapsed/refractory AML. Incorporated in 1990, Geron is headquartered in Foster City, California.
Geron Corporation is a commercial-stage biopharmaceutical company focused on developing therapeutics for oncology. Its lead product, RYTELO, is a telomerase inhibitor approved for treating adult patients with low- to intermediate-1 risk myelodysplastic syndromes (MDS) with transfusion-dependent anemia. The company also has a robust pipeline including IMerge (Phase 3 for lower-risk MDS), IMpactMF (Phase 3 for relapsed/refractory myelofibrosis), Impress (Phase 2 for higher-risk MDS and acute myeloid leukemia), IMproveMF (Phase 1 for frontline myelofibrosis), and IMAGINE (Phase 1/2 for relapsed/refractory AML). Geron's expertise lies in telomerase inhibition, a novel approach to cancer treatment.
Where is Geron Corporation (GERN) listed and what currency does it trade in?
Geron Corporation is listed on the Nasdaq Global Select Market (NasdaqGS) under the ticker symbol GERN. Its shares are traded in United States Dollars (USD). As a US-based company, it is subject to the reporting and regulatory requirements of the US Securities and Exchange Commission (SEC). The NasdaqGS is a major US stock exchange known for listing many biotechnology and technology companies, providing liquidity and visibility for Geron's stock.
What sector and industry does Geron Corporation (GERN) operate in?
Geron Corporation operates in the Healthcare sector, specifically within the Biotechnology industry. As a biotechnology company, it focuses on researching, developing, and commercializing innovative therapies for serious diseases, primarily cancer. The biotechnology industry is characterized by high research and development costs, long development timelines, and significant regulatory oversight. Geron's work in telomerase inhibition places it at the forefront of a niche area within oncology, targeting the biology of telomeres to inhibit cancer cell growth.
Where is Geron Corporation (GERN) headquartered and what markets does it serve?
Geron Corporation is headquartered in Foster City, California, United States. The company primarily serves the US market, as indicated by its country and region designation. While its clinical trials and commercial activities are focused in the US, the company's therapies, if approved, could potentially address global oncology needs. The headquarters in Foster City places Geron in the San Francisco Bay Area, a major hub for biotechnology innovation, providing access to talent, research collaborations, and investment capital.
What is Geron Corporation's (GERN) business model and how does it generate revenue?
Geron Corporation is a commercial-stage biopharmaceutical company that generates revenue primarily through the sale of its approved product, RYTELO, a telomerase inhibitor for myelodysplastic syndromes. As a biotechnology company, its business model involves significant investment in research and development to advance its pipeline of drug candidates through clinical trials. If successful, these candidates can receive regulatory approval and be commercialized, either directly or through partnerships. Geron's pipeline includes multiple programs in various stages of clinical development, targeting indications such as myelofibrosis and acute myeloid leukemia, which could provide future revenue streams. The company's focus on telomerase inhibition represents a unique therapeutic approach that may offer competitive advantages in the oncology market.